CN102784159B - Compound synergistic tartaric acid tylosin for injection of livestock - Google Patents
Compound synergistic tartaric acid tylosin for injection of livestock Download PDFInfo
- Publication number
- CN102784159B CN102784159B CN 201210277167 CN201210277167A CN102784159B CN 102784159 B CN102784159 B CN 102784159B CN 201210277167 CN201210277167 CN 201210277167 CN 201210277167 A CN201210277167 A CN 201210277167A CN 102784159 B CN102784159 B CN 102784159B
- Authority
- CN
- China
- Prior art keywords
- tylosin
- injection
- tartaric acid
- trimethoprim
- livestock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007924 injection Substances 0.000 title claims abstract description 36
- 238000002347 injection Methods 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 229930194936 Tylosin Natural products 0.000 title abstract description 11
- 239000004182 Tylosin Substances 0.000 title abstract description 11
- 229960004059 tylosin Drugs 0.000 title abstract description 11
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 title abstract description 11
- 235000019375 tylosin Nutrition 0.000 title abstract description 11
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 title abstract description 9
- 244000144972 livestock Species 0.000 title abstract description 6
- 239000011975 tartaric acid Substances 0.000 title abstract 8
- 235000002906 tartaric acid Nutrition 0.000 title abstract 8
- 230000002195 synergetic effect Effects 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 36
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims abstract description 31
- 229960002064 kanamycin sulfate Drugs 0.000 claims abstract description 31
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 31
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000001384 succinic acid Substances 0.000 claims abstract description 11
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical group Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001309 procaine hydrochloride Drugs 0.000 claims abstract description 10
- 239000006184 cosolvent Substances 0.000 claims abstract description 8
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims abstract description 8
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims abstract description 8
- ICVKYYINQHWDLM-KBEWXLTPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 ICVKYYINQHWDLM-KBEWXLTPSA-N 0.000 claims description 49
- 229960001717 tylosin tartrate Drugs 0.000 claims description 49
- 241001465754 Metazoa Species 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002131 composite material Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 16
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 230000000845 anti-microbial effect Effects 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 208000003322 Coinfection Diseases 0.000 abstract description 2
- 206010028470 Mycoplasma infections Diseases 0.000 abstract description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 18
- 238000012856 packing Methods 0.000 description 18
- 238000007689 inspection Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000011265 semifinished product Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000011835 investigation Methods 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 239000000273 veterinary drug Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000204003 Mycoplasmatales Species 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940051027 pasteurella multocida Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound synergistic tartaric acid tylosin for injection of livestock and aims at providing a compound synergistic tartaric acid tylosin, which can be used for achieving a rapid and definite curative effect on the breathing system infection and complications of livestock, for injection of livestock. The medicine comprises the following components in parts by weight: 1 part of tartaric acid tylosin, 1 part of kanamycin sulfate, 0.2 parts of trimethoprim, 0.2 parts of cosolvent and 0.05-0.1 parts of pain alleviator, wherein the cosolvent is citric acid or succinic acid or a combination of the citric acid and the succinic acid; and the pain alleviator is procaine hydrochloride or lidocaine hydrochloride or a combination of procaine hydrochloride and the lidocaine hydrochloride. The compound synergistic tartaric acid tylosin for injection of livestock contains medicine components of three types, namely tartaric acid tylosin, kanamycin sulfate and trimethoprim, can be used for solving the problems that tartaric acid tylosin is narrow in antimicrobial spectrum and cannot well control secondary infection during the treatment of mycoplasma infection and the problem that trimethoprim is insoluble in water, and achieving a synergy effect on tartaric acid tylosin and kanamycin sulfate, and is accurate in dosage and convenient in use.
Description
Technical field
The present invention relates to injection use compound potentiation tylosin tartrate for animals.
Background technology
From present China Developing of Animal Industry situation, current poultry respiratory system infection is occurred frequently, complication is seriously big to poultry harm.The medicine that does not also have comparatively desirable treating both the principal and secondary aspects of a disease now on the market.By investigation domestic, the international market is found that market presses for a kind of efficacy stability, good effect, stable high, easy to use, complication serious specific medicine occurred frequently to the poultry respiratory system infection.
In the prior art, tylosin tartrate belongs to vinegar class animal specific antibacterials in the macro ring, mainly most gram-positive bacterias, Gram-negative coccus, anaerobe level legionella, mycoplasma, chlamydia is had good action.Belong to the quick-acting antibacterial of trophophase.Under high concentration, have bactericidal action, be the macrolide apoplexy due to endogenous wind to one of the strongest medicine of mycoplasma effect, be mainly used in preventing and treating pig, fowl mycoplasma, as the mycoplasma pneumonia of chronic respiratory disease of fowl (CRD) and infectiousness hole chamber inflammation and pig.
The antimicrobial spectrum of kanamycin sulfate is similar to streptomycin, but effect is strong slightly.Most of gram negative bacterias such as escherichia coli, Bacillus proteus, Salmonella and pasteurella multocida etc. there are powerful antibacterial action, also responsive to gold-coloured staphylococci and tubercule bacillus.Intramuscular injection is used for the various severe infections due to the sensitive organism, as septicemia, urogenital infection, respiratory tract infection, skin and soft tissue infection etc.
Trimethoprim is the broad-spectrum antiseptic synergist, can the antibacterial action of multiple antibiotics be increased substantially (but potentiation several times to tens times), and can reduce the appearance of drug resistance strain.
Injection means interior sterile solution, emulsion or the suspension of confession injection body that medicine is made, and for the sterilized powder concentrated solution of facing with preceding wiring solution-forming or suspension.The characteristics of injection mainly show route of administration without digestive system and defend tissue (liver) and direct injection tissue or blood vessel, so drug effect are rapid, is applicable to first aid.But also the curative effect of some injection is extended, to adapt to the needs in the medical treatment.The dosage of injection is accurate, and reliable effect may suffer influences such as Digestive system, food, and make the dosage of taking that curative effect can not take place fully unlike endo-medicine.In addition, can make some drugs performance positioning action again.
Injectable sterile powder claims the powder pin again, faces with preceding and injects with sterilized water for injection dissolving back, and be a kind of injection type commonly used.Be applicable to unsettled medicine in water, particularly to damp and hot sensitive antibiotics and biological product.
Summary of the invention
The purpose of this invention is to provide a kind of injection use compound potentiation tylosin tartrate for animals, it has quick, definite curative effect to poultry respiratory system infection and complication.
For achieving the above object, the technical solution adopted in the present invention is: a kind of injection use compound potentiation tylosin tartrate for animals, it is characterized in that, and formed by following components in part by weight:
Amounts of components is strict in the described prescription, and other component does not almost have the leeway of adjustment except pain relief agents.Only can do following replacement in material choice:
Described cosolvent is that citric acid or succinic acid or the two are composite.
Described pain relief agents is that procaine hydrochloride or lidocaine hydrochloride or the two are composite.
The preparation method of injection of the present invention:
Take by weighing trimethoprim, the cosolvent of recipe quantity, mix by fluid energy mill and pulverize, cross 120 orders or thinner sieve;
Again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases;
Inspection of semifinished product content, dissolubility, qualified back packing, packing, namely.
Further, described pulverizing is to pulverize through fluid energy mill.
Further, described sieving to crossing 120 mesh sieves.
The usage of product of the present invention and consumption: earlier product of the present invention is used analog dissolvings such as solvent for injection such as water for injection or ethylene glycol, ethanol, muscle or subcutaneous injection then.In tylosin tartrate: amount once, every 1kg body weight, pig, fowl 5～13mg, once a day.
The injection use compound potentiation tylosin tartrate for animals of the present invention's development includes tylosin tartrate, kanamycin sulfate, three kinds of pharmaceutical compositions of trimethoprim.Three kinds of ingredients composite not only at indication more extensive, and enhancing evident in efficacy.And have a following effect of having a mind to:
1, develops for veterinary clinic a kind of injection use compound potentiation tylosin tartrate for animals and preparation method thereof is provided;
2, solved because the tylosin tartrate narrow antimicrobial spectrum, can not fine control secondary infection during the treatment mycoplasma infection;
3, solve the problem that trimethoprim is insoluble in water, and paratartaric acid tylosin and kanamycin sulfate potentiation;
4, be injectable sterile powder, preparation stabilization, storage period is long;
5, rapid-action, duration of efficacy is long, the bioavailability height;
6, use safety, determined curative effect, quality controllable;
7, dosage is accurate, and is easy to use;
8, irritating property is little, reduce to poultry stress.
The specific embodiment
Embodiment one
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, citric acid 0.2g, procaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the citric acid of recipe quantity respectively, mix by fluid energy mill and pulverize, cross 120 mesh sieves, again with tylosin tartrate, kanamycin sulfate, procaine hydrochloride by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, namely.
Embodiment two
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, succinic acid 0.2g, procaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the succinic acid of recipe quantity respectively, mix by fluid energy mill and pulverize, cross 120 mesh sieves, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Embodiment three
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, citric acid 0.2g, lidocaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the citric acid of recipe quantity respectively, mix by fluid energy mill and pulverize, cross 150 mesh sieves, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Embodiment four
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, succinic acid 0.2g, lidocaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the succinic acid of recipe quantity respectively, mix by fluid energy mill and pulverize, cross 120 mesh sieves, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Embodiment five
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, citric acid 0.1g, procaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the citric acid of recipe quantity respectively, mix by fluid energy mill and pulverize, cross 120 mesh sieves, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Embodiment six
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, succinic acid 0.1g, procaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the succinic acid of recipe quantity respectively, mix by fluid energy mill and pulverize, sieve, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Embodiment seven
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, citric acid 0.1g, procaine hydrochloride 0.03g, lidocaine hydrochloride 0.02g.
Preparation method:
Take by weighing trimethoprim, the cosolvent of recipe quantity respectively, mix by fluid energy mill and pulverize, cross 120 mesh sieves, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Embodiment eight
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, citric acid 0.05g, succinic acid 0.05g, lidocaine hydrochloride 0.05g.
Preparation method:
Take by weighing trimethoprim, the cosolvent of recipe quantity respectively, mix by fluid energy mill and pulverize, sieve, again with tylosin tartrate, kanamycin sulfate, pain relief agents by the equivalent method mix homogeneously that progressively increases, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, namely.
Result of study
1, prescription research
The present invention writes out a prescription with crude drug tylosin tartrate, kanamycin sulfate, trimethoprim, records one one of " Chinese veterinary drug allusion quotation " version in 2010." Chinese veterinary drug allusion quotation " record, similar to the erythromycin antimicrobial spectrum.A little less than the effect to antibacterial, strong to the Mycoplasma effect, be that the macrolide apoplexy due to endogenous wind is to one of the strongest medicine of mycoplasma effect.Sensitive organism produces drug resistance to this product, and staphylococcus aureus has part crossing drug resistant phenomenon to this product and erythromycin; The antimicrobial spectrum of kanamycin sulfate is similar to streptomycin, but effect is strong slightly.Most of gram negative bacterias such as escherichia coli, Bacillus proteus, Salmonella and pasteurella multocida etc. there are powerful antibacterial action, also responsive to gold-coloured staphylococci and tubercule bacillus.Intramuscular injection is used for the various severe infections due to the sensitive organism, as septicemia, urogenital infection, respiratory tract infection, skin and soft tissue infection etc.; Trimethoprim is the broad-spectrum antiseptic synergist, can the antibacterial action of multiple antibiotics be increased substantially, and can reduce the appearance of drug resistance strain.
The present invention's prescription is with tylosin tartrate, kanamycin sulfate drug combination, through trimethoprim potentiation, clinical trial shows, in the effect and purposes basis of " Chinese veterinary drug allusion quotation " record, the pain that produces in the time of solving the tylosin tartrate injection, control livestock and poultry respiratory and digestive tract disease effect are more remarkable, and reduce chemical sproof generation.
2, stability study
Injection use compound potentiation tylosin tartrate product stability research for animals of the present invention, " veterinary drug stability test technical specification (trying) " way that system promulgates according to the Ministry of Agriculture, adopt temperature, humidity accelerated test and acceleration by light test, three batch samples are carried out stability study.
2.1 temperature, humidity accelerated test
2.1.1 test material
Product of the present invention: injection use compound potentiation tylosin tartrate for animals
Batch number: 110701,110702,110703
Product requirement: commercially available back
2.1.2 experimental condition: adopt the medicine stability test case, temperature transfers to 40 ± 2 ℃, and relative humidity is controlled 75 ± 5%.
2.1.3 observing time: product of the present invention was placed 6 months, and at duration of test, each month sampling secondary detects product by stable high spot reviews project.
2.1.4 investigation project: character, content, the investigation project is determined according to " veterinary drug stability test technical specification (the trying) " way for Ministry of Agriculture's promulgation.
2.1.5 test data
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110701
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110702
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110703
2.2 acceleration by light test
2.2.1 test material
Product of the present invention: injection use compound potentiation tylosin tartrate for animals
Batch number: 110701,110702,110703
Product requirement: commercially available back
2.2.2 experimental condition: use in the proof box of medicine strong illumination in test, illumination is 4500 native 500LX
2.2.3 observing time: get product of the present invention and pack in the water white transparency container, be positioned in the light durability proof box, placed ten days under the condition of illumination 4500LX ± 500LX, sampling when walking in the 5th, ten day detects by stable high spot reviews project.
2.2.4 investigation project: character, pH value, clarity, content, investigation project are determined according to " veterinary drug stability test technical specification (the trying) " way for Ministry of Agriculture's promulgation.
2.2.5 test data
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110701
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110702
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110703
2.3 result of study: product three batch samples of the present invention are investigated by temperature, humidity accelerated test and first accelerated test, the result shows that product characteristics, pH value, clarity, content etc. detect in each investigation time all up to specification, compares every detection index with the O month and do not have significant degreeization.
3. the clinical trial of injection use compound potentiation tylosin tartrate for animals
Method: choose ill moving, be divided into experimental group, matched group 1 and matched group 2 at random:
(1) drug test group intramuscular injection injection use compound potentiation tylosin tartrate for animals of the present invention;
(2) medicine matched group 1 intramuscular injection injection tylosin tartrate matched group; Manufacturer: animal pharmaceutcal corporation, Ltd of Chongqing gold nation, effective ingredient: tylosin tartrate, trimethoprim.
(3) medicine matched group 2 intramuscular injections kanamycin sulfate matched group; Manufacturer: animal pharmaceutcal corporation, Ltd of the golden nation of gold celebrating, effective ingredient: kanamycin sulfate, trimethoprim.
Therapeutic dose: test group is in tylosin, 1kg body weight 5mg; Matched group 1 is in tylosin, 1kg body weight 10mg; Matched group 2 is in kanamycin sulfate, 1kg body weight 10mg.After the treatment beginning, with identical administering mode and corresponding disease, record infected animal health situation of change every day, treat and add up therapeutic outcome after 2 days.
The result shows that the matched group 1 of injection use compound potentiation tylosin tartrate for animals and folk prescription medicine, 2 is relatively treated disease effects and obviously is better than matched group.The compound of the more existing tylosin tartrate of curative effect and trimethoprim or the compound of kanamycin sulfate and trimethoprim significantly strengthen.Disease complete obiteration with animal is healing.
The clinical application effect statistics of injection use compound potentiation tylosin tartrate for animals
Claims (2)
1. an injection use compound potentiation tylosin tartrate for animals is characterized in that, is made up of following components in part by weight:
1 part of tylosin tartrate;
1 part of kanamycin sulfate;
0.2 part of trimethoprim;
0.2 part of cosolvent;
0.05～0.1 part of pain relief agents;
Described cosolvent is that citric acid or succinic acid or the two are composite.
2. a kind of injection use compound potentiation tylosin tartrate for animals according to claim 1 is characterized in that: described pain relief agents is that procaine hydrochloride or lidocaine hydrochloride or the two are composite.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210277167 CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
| CN201310364033.XA CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210277167 CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310364033.XA Division CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
| CN201310363449.XA Division CN103405464B (en) | 2012-08-06 | 2012-08-06 | Medicine for treating respiratory system infection of livestock and poultry |
| CN201310364326.8A Division CN103405466B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tylosin tartrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784159A CN102784159A (en) | 2012-11-21 |
| CN102784159B true CN102784159B (en) | 2013-08-21 |
Family
ID=47149880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210277167 Expired - Fee Related CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
| CN201310364033.XA Expired - Fee Related CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310364033.XA Expired - Fee Related CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102784159B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104926899A (en) * | 2015-05-11 | 2015-09-23 | 成都中牧生物药业有限公司 | Preparation process avoiding the reduction of tylosin tartrate original drug potency |
| CN104892705A (en) * | 2015-05-11 | 2015-09-09 | 成都中牧生物药业有限公司 | Preparation technology of tylosin tartrate for injection |
| CN107308176A (en) * | 2017-07-05 | 2017-11-03 | 山东中牧兽药有限公司 | A kind of injection Tylosin Tartrate and preparation method thereof |
| CN115068420A (en) * | 2022-07-27 | 2022-09-20 | 石家庄石牧药业有限公司 | Tylosin tartrate solution for livestock and poultry and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843329A (en) * | 2006-05-17 | 2006-10-11 | 天津生机集团有限公司 | Compound amikacin sulfate injection for animal and its preparation method |
| CN101468032A (en) * | 2007-12-26 | 2009-07-01 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating respiratory illness of livestock and poultry |
| CN101822688B (en) * | 2010-05-19 | 2012-01-11 | 陈建波 | Compound tylosin injection for animals and preparation method thereof |
-
2012
- 2012-08-06 CN CN 201210277167 patent/CN102784159B/en not_active Expired - Fee Related
- 2012-08-06 CN CN201310364033.XA patent/CN103432150B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103432150A (en) | 2013-12-11 |
| CN103432150B (en) | 2015-12-09 |
| CN102784159A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101953841B (en) | Swine eperythrozoonosis-resisting compound long-acting oxytetracycline injection and preparation method thereof | |
| CN102784159B (en) | Compound synergistic tartaric acid tylosin for injection of livestock | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN105943629A (en) | Traditional Chinese medicine compound preparation for treating piglet diarrhea and preparation method thereof | |
| CN102784158B (en) | Preparation method of compound synergy tylosin tartrate for veterinary injection | |
| CN103405463A (en) | Preparation method of synergistic tylosin tartrate soluble powder compound medicine | |
| CN103405465A (en) | Preparation method of medicine for treating respiratory system infection of livestock and poultry | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN103405466B (en) | Compound synergistic tylosin tartrate | |
| CN102813909B (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN100548306C (en) | A kind of injection and preparation technology thereof who treats eperythrozoonosis of domestic animal | |
| CN103405464B (en) | Medicine for treating respiratory system infection of livestock and poultry | |
| CN101829129B (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN103169652A (en) | Veterinary alkaline lincomycin injection as well as preparation method and use thereof | |
| CN102755337A (en) | Compound florfenicol injection and preparation method thereof | |
| CN103432151A (en) | Preparation method for compound synergistic tylosin tartrate | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| CN110151779A (en) | A kind of composition that treating batrachia torticollis disease and its application | |
| CN105456281B (en) | A kind of veterinary medical composition and its production and use | |
| RU2574025C2 (en) | Agent for treatment of acute gastrointestinal diseases of newborn lambs | |
| CN102973583B (en) | Compound gentamicin sulphate composition for treating poultry diarrhea and preparation method thereof | |
| CN104758391B (en) | Stop dysentery compound Chinese medicinal preparation and its production method for animals | |
| CN103622976B (en) | Long-acting veterinary compound doxycycline hydrochloride injection and preparation method thereof | |
| CN103054891A (en) | Compound erythromycin thiocyanate composition for controlling poultry bacterial and mycoplasma infection and preparation method thereof | |
| CN104208049A (en) | Application of bronopol and analogue thereof in drug preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121121 Assignee: Sichuan Lanme Biological Pharmaceutical Co., Ltd. Assignor: Sichuan Deruntong Biotechnology Co., Ltd. Contract record no.: 2013510000094 Denomination of invention: Preparation method of compound synergy tylosin tartrate for veterinary injection Granted publication date: 20130821 License type: Exclusive License Record date: 20130922 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20170223 Granted publication date: 20130821 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20170823 Granted publication date: 20130821 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20180806 |